Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization

Acta Ophthalmologica

Volumn 88, Issue 8, 2010, Pages

  Forte, Raimondo ^a   Cennamo, Gilda ^a   Finelli, Marialuisa ^a   Cesarano, Ida ^a   D'Amico, Giuseppe ^a   De Crecchio, Giuseppe ^a   Cennamo, Giovanni ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

age related macular degeneration; anti VEGF; as needed treatment

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN;

AGED; ARTICLE; CATARACT; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; ENDOPHTHALMITIS; EYE TOXICITY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; MALE; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA FOVEA; RETINA MACULA DEGENERATION; RETINA TEAR; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; THROMBOSIS; UVEITIS; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FOVEA CENTRALIS; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; PROGNOSIS; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 78649876246     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2010.02021.x     Document Type: Article

References (43)

1. Aiello LP, Brucker AJ, Chang S, et al. (2004): Evolving guidelines for intravitreous injections. Retina 24: S3-S19.
2. Armaly ME, (1965): Statistical attributes of the steroid hypertensive response in the clinically normal eye, I: the demonstration of three levels of response. Invest Ophthalmol 4: 187-197.
3. Atmani K, Coscas F, Coscas G, &, Soubrane G, (2009): Pegaptanib sodium for occult choroidal neovascularization in neovascular age-related macular degeneration: a prospective case series. Eye 23: 1150-1154.
4. Augustin AJ, &, Schmidt-Erfurth U, (2006): Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113: 14-22.
5. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, &, Giust MJ, (2006): Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113: 1695.e1-15.
6. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, &, Ianchulev T,; ANCHOR Study Group (2009): Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116: 57-65.e5.
7. Butcher JM, Austin M, McGalliard J, &, Bourke RD, (1994): Bilateral cataracts and glaucoma induced by long term use of steroid eye drops. BMJ 309: 43.
8. Ciulla TA, Criswell MH, Danis RP, &, Hill TE, (2001): Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 119: 399-404.
9. Costagliola C, Romano M, Corte MD, Perrotta R, Menzione M, Rinaldi M, Semeraro F, &, Parmeggiani F, (2009): Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study. Retina 29: 1227-1234.
10. Fung AE, Rosenfeld PJ, &, Reichel E, (2006): The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90: 1344-1349.
11. Furino C, Boscia F, Recchimurzo N, Besozzi G, Cardascia N, Sborgia L, Niro A, &, Sborgia C, (2009): Intravitreal bevacizumab for treatment-na®ve subfoveal occult choroidal neovascularization in age-related macular degeneration. Acta Ophthalmol 87: 404-407.
12. Garg S, Brod R, Kim D, Lane RG, Maguire J, &, Fischer D, (2008): Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. Clin Experiment Ophthalmol 36: 252-256.
13. Gelisken F, Ziemssen F, Voelker M, Bartz-Schmidt KU, &, Inhoffen W, (2009): Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration. Eye 23: 694-702.
14. Gillies MC, &, Larsson J, (2007): The effect of intravitreal triamcinolone on foveal edema in exudative macular degeneration. Am J Ophthalmol 144: 134-136.
15. Gillies MC, Simpson JM, &, Luo W, (2003): A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 121: 667-673.
16. Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, &, Fu A, (2007): Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina 27: 432-438.
17. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, &, Guyer DR, (2004): Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816.
18. Jonas JB, &, Sofker A, (2001): Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular oedema. Am J Ophthalmol 132: 425-427.
19. Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, &, Degenring R, (2003): Intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Br J Ophthalmol 87: 462-468.
20. Jonas JB, Strueven V, Kamppeter BA, Harder B, Spandau UH, &, Schlichtenbrede F, (2006): Visual acuity change after intravitreal triamcinolone in various types of exudative age-related macular degeneration. J Ocul Pharmacol Ther 22: 370-376.
21. Jonas JB, Ihloff AK, Harder B, Kreissig I, Schlichtenbrede F, Libondi T, Spandau UH, &, Vossmerbaeumer U, (2009): Intravitreal bevacizumab versus triamcinolone acetonide for exudative age-related macular degeneration. Ophthalmic Res 41: 21-27.
22. Kaiser PK,; for the Visudyne In Occult CNV (VIO) study group (2009): Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial. Curr Med Res Opin 25: 1853-1860.
23. Kaiser PK, Blodi BA, Shapiro H, &, Acharya NR,; MARINA Study Group (2007): Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114: 1868-1875. Epub 2007 July 12.
24. Larsson J, Zhu M, Sutter F, &, Gillies MC, (2005): Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol 139: 802-806.
25. Lee J, Freeman WR, Azen SP, Chung EJ, &, Koh HJ, (2007): Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: one-year results. Retina 27: 1205-1213.
26. Leydolt C, Michels S, Prager F, Garhoefer G, Georgopoulos M, Polak K, &, Schmidt-Erfurth U, (2010): Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results. Acta Ophthalmol 88: 594-600.
27. Lommatzsch A, Heimes B, Gutfleisch M, Spital G, Zeimer M, &, Pauleikhoff D, (2009): Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. Eye (Lond) 23: 2163-2168.
28. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, &, Venkatraman AS, (2005): Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112: 1035-1047.
29. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, &, Roth M, (1998): Corticosteroids inhibit the expression of vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 341: 309-315.
30. Noma H, Funatsu H, Yamasaki M, et al. (2008): Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 22: 42-48.
31. Penfold PL, Wen L, Madigan MC, Gillies MC, King NJ, &, Provis JM, (2000): Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol 121: 458-465.
32. Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, &, Bartz-Schmidt KU, (2007): Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143: 995-1002.
33. Quiram PA, Hassan TS, &, Williams GA, (2007): Treatment of na®ve lesions in neovascular age-related macular degeneration with pegaptanib. Retina 27: 851-856.
34. Rich RM, Rosenfeld PJ, Puliafito CA, et al. (2006): Short term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26: 495-511.
35. Rosenfeld PJ, (2006): Intravitreal Avastin: the low cost alternative to Lucentis? Am J Ophthalmol 142: 141-143.
36. Rosenfeld PJ, Moshfeghi AA, &, Puliafito CA, (2005): Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36: 331-335.
37. Sivaprasad S, Acharya N, &, Hykin P, (2008): Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK. Clin Ophthalmol 2: 347-354.
38. Spaide RF, Laud K, Fine HF, et al. (2006): Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26: 383-390.
39. Steen B, Sejersen S, Berglin L, Seregard S, &, Kvanta A, (1998): Matrix metalloproteinases and metalloproteinase inhibitor in choroidal neovascular membranes. Invest Ophthalmol Vis Sci 39: 2194-2200.
40. Sutter FK, Simpson JM, &, Gillies MC, (2004): Intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment: 3-month efficacy and safety results of a prospective, randomized, doublemasked, placebo-controlled clinical trial. Ophthalmology 111: 2044-2049.
41. West SK, (2000): Looking forward to 20/20: a focus on the epidemiology of eye diseases. Epidemiol Rev 22: 64-70.
42. Van Wijngaarden P, Coster DJ, &, Williams KA, (2005): Inhibitors of ocular neovascularization: promises and potential problems. JAMA 293: 1509-1513.
43. Wong LJ, Desai RU, Jain A, Feliciano D, Moshfeghi DM, Sanislo SR, &, Blumenkranz MS, (2008): Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina 28: 1151-1158.